KES
Search
- Page Path
- HOME > Search
Original Article
- Diabetes, Obesity and Metabolism
- Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
- Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh
- Endocrinol Metab. 2021;36(3):647-660. Published online June 18, 2021
- DOI: https://doi.org/10.3803/EnM.2020.934
- 6,205 View
- 302 Download
- 13 Web of Science
- 14 Crossref
-
Abstract
PDF
Supplementary Material
PubReader 
ePub - Background
Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters.
Methods
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Results
We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was −4.19 kg (95% confidence interval [CI], −4.84 to −3.55), with a −4.16% change from the baseline (95% CI, −4.90 to −3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: −1.55; 95% CI, −1.76 to −1.34) and waist circumference (MD: −3.11 cm; 95% CI, −3.59 to −2.62) and significantly decreased blood pressure (systolic blood pressure, MD: −2.85 mm Hg; 95% CI, −3.36 to −2.35; diastolic blood pressure, MD: −0.66 mm Hg; 95% CI, −1.02 to −0.30), glycated hemoglobin (MD: −0.40%; 95% CI, −0.49 to −0.31), and low-density lipoprotein cholesterol (MD: –2.91 mg/dL; 95% CI, −5.28 to −0.53; MD: −0.87% change from baseline; 95% CI, −1.17 to −0.56).
Conclusion
Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people. -
Citations
Citations to this article as recorded by
- Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome.2024;[Epub] CrossRef - Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
Journal of Obesity.2024; 2024: 1. CrossRef - Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
European Journal of Gastroenterology & Hepatology.2023; 35(1): 1. CrossRef - Recommendations for the prevention and management of obesity in the Iraqi population
Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
Postgraduate Medicine.2023; 135(5): 425. CrossRef - A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
Life.2023; 13(4): 1012. CrossRef - Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Juyoung Shin, Raeun Kim, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49. CrossRef - The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
Frontiers in Endocrinology.2023;[Epub] CrossRef - Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
Hao Gou, Yiman Zhai, Junjun Guo
European Journal of Pediatrics.2023; 182(11): 5095. CrossRef - Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
Endocrine.2022; 75(3): 718. CrossRef - Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C. W. Lau, Rachel L Batterham, Carel W. le Roux
Expert Review of Clinical Pharmacology.2022; 15(3): 251. CrossRef - Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
American Journal of Therapeutics.2022; 29(4): e410. CrossRef - GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
Trends in Endocrinology & Metabolism.2022; 33(9): 628. CrossRef - Targeting skeletal muscle mitochondrial health in obesity
Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
Clinical Science.2022; 136(14): 1081. CrossRef - A Study on Weight Loss Cause as per the Side Effect of Liraglutide
Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
Cardiovascular Therapeutics.2022; 2022: 1. CrossRef
- Pharmacotherapy for obesity: moving towards efficacy improvement
First
Prev
